Ojjaara
(oh-JAR-uh)
A drug used to treat intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF, in adults with anemia. Ojjaara blocks JAK and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called momelotinib dihydrochloride monohydrate.